Happy 4th of July from the Certified-Pep Team
Use Coupon Code FREEDOM
for 35% off everything but BAC
CJC / IPA 10/10 MG
$111.00
Research Growth Hormone Secretagogue Blend (CJC-1295 NO DAC / Ipamorelin) 1× 10mg / 10mg
Key Features
- Dual-peptide research blend targeting GH signaling pathways
- Lyophilized for stability and precise laboratory handling
- Analytical QC ensures batch consistency and purity
Research Peptide (KPV) — 10 MG
Key Features
- Short-chain peptide research compound for signaling pathway studies
- Lyophilized for stability and precise laboratory handling
- QC verified for identity and batch consistency
Certificate of Analysis
The Hulk (CJC-1295 No DAC + Ipamorelin) 20 mg is a dual-peptide research formulation combining CJC-1295 (No DAC) and Ipamorelin into a single lyophilized vial. This consolidated presentation contains 10 mg of CJC-1295 No DAC and 10 mg of Ipamorelin, providing a total peptide content of 20 mg while replacing prior multi-vial formats.
CJC-1295 No DAC is a synthetic growth-hormone–releasing hormone (GHRH) analog commonly investigated in preclinical research for its interaction with pituitary GHRH receptors and its role in stimulating pulsatile growth-hormone signaling. Unlike DAC-modified variants, the No-DAC form is characterized by a shorter active window, making it a subject of interest in studies examining endogenous growth-hormone pulse dynamics and regulatory feedback mechanisms.
Ipamorelin is a selective ghrelin-receptor (GHS-R) agonist studied for its ability to stimulate growth-hormone release through a pathway distinct from GHRH analogs, with minimal interaction with other pituitary hormones in experimental models. Research attention has focused on its receptor selectivity, signaling kinetics, and compatibility with GHRH-based compounds.
When paired in a single formulation, CJC-1295 No DAC and Ipamorelin represent complementary growth-hormone–signaling mechanisms—one acting through the GHRH receptor pathway and the other through ghrelin-receptor activation. This combination is frequently examined in research settings to evaluate coordinated or synergistic effects on growth-hormone pulse amplitude, frequency, and downstream signaling cascades.
Current areas of research interest for the CJC-1295 No DAC + Ipamorelin combination include:
- Growth-hormone secretion dynamics, including pulse frequency and amplitude modulation
- Pituitary signaling and receptor-pathway interaction studies
- Metabolic and body-composition research models evaluating GH-mediated signaling effects
- Recovery and adaptation studies examining endocrine responses to physiological stress
- Sleep-cycle and circadian-rhythm research related to endogenous GH release patterns
This single-vial Hulk formulation is manufactured to 99% purity as verified by HPLC analysis and is intended strictly for laboratory and research use.
Not for human or veterinary use.
